Visual Abstract

Visual Abstract
Visual Abstract
View largeDownload slide
Keywords:
Chronic kidney disease, Secondary hyperparathyroidism, Vitamin D insufficiency, 25-Hydroxyvitamin D, Extended-release calcifediol, Bone turnover markers

Background: Vitamin D repletion is recommended for secondary hyperparathyroidism (SHPT) and associated vitamin D insufficiency (VDI) in chronic kidney disease (CKD), but optimal levels of serum total 25-hydroxyvitamin D remain undefined. Clinical practice guidelines target sufficiency, whereas recent data indicate that higher levels are required to control the elevation of intact parathyroid hormone (iPTH) as CKD advances. This secondary analysis of 2 randomized controlled trials seeks to identify the minimum level of mean serum 25-hydroxyvitamin D required to control SHPT arising from VDI in stage 3 or 4 CKD. Methods: Adult subjects (n = 429) with SHPT, VDI, and stage 3 or 4 CKD were stratified by stage and treated daily with either extended-release calcifediol (ERC) or placebo in 2 identical, parallel, randomized, double-blind studies. After treatment for 26 weeks, all subjects were ranked by the level of serum total 25-hydroxyvitamin D and divided into quintiles in order to examine the relationships between the degree of vitamin D repletion and the associated changes in plasma iPTH, serum bone turnover markers, calcium, phosphorus, intact fibroblast growth factor 23 (FGF23) and vitamin D metabolites, estimated glomerular filtration rate (eGFR), and urine calcium:creatinine (Ca:Cr) ratio. Results: Progressive increases in serum 1,25-dihydroxyvitamin D and reductions in plasma iPTH and serum bone turnover markers were observed as mean posttreatment serum 25-hydroxyvitamin D rose from 13.9 ng/mL (in Quintile 1) to 92.5 ng/mL (in Quintile 5), irrespective of CKD stage. Mean serum calcium, phosphorus and FGF23, eGFR, and urine Ca:Cr ratio (collectively “safety parameters”) did not significantly change from Quintile 1. Suppression of iPTH and bone turnover markers was not observed until serum 25-hydroxyvitamin D rose to at least 50.8 ng/mL (Quintile 3). Conclusion: ERC therapy produced exposure-dependent reductions in plasma iPTH and bone turnover markers only when mean serum total 25-hydroxyvitamin D reached at least 50.8 ng/mL, indicating that current targets for vitamin D repletion therapy in CKD are too low. Gradual elevation of mean serum 25-hydroxyvitamin D to 92.5 ng/mL was not associated with significant adverse changes in safety parameters.

Keywords:
Chronic kidney disease, Secondary hyperparathyroidism, Vitamin D insufficiency, 25-Hydroxyvitamin D, Extended-release calcifediol, Bone turnover markers
1.
Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.
Clin J Am Soc Nephrol
. 2011 Apr; 6(4): 913–21.
2.
Nigwekar SU, Tamez H, Thadhani RI. Vitamin D and chronic kidney disease-mineral bone disease (CKD-MBD).
Bonekey Rep
. 2014 Feb; 3: 498.
3.
González EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study.
Am J Nephrol
. 2004 Sep-Oct; 24(5): 503–10.
4.
Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease.
Kidney Int
. 2007 Jan; 71(1): 31–8.
5.
National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:S1-201.
6.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
Kidney Int Suppl
. 2009 Aug;(113):S1-130.
7.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD).
Kidney Int Suppl
(2011). 2017 Jul; 7(1): 1–59.
8.
Agarwal R, Georgianos PI. Con: nutritional vitamin D replacement in chronic kidney disease and end-stage renal disease.
Nephrol Dial Transplant
. 2016 May; 31(5): 706–13.
9.
Kalantar-Zadeh K, Kovesdy CP. Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease.
Clin J Am Soc Nephrol
. 2009 Sep; 4(9): 1529–39.
10.
Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al.; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline.
J Clin Endocrinol Metab
. 2011 Jul; 96(7): 1911–30.
11.
Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know.
J Clin Endocrinol Metab
. 2011 Jan; 96(1): 53–8.
12.
Sprague SM, Silva AL, Al-Saghir F, Damle R, Tabash SP, Petkovich M, et al. Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease.
Am J Nephrol
. 2014; 40(6): 535–45.
13.
Ennis JL, Worcester EM, Coe FL, Sprague SM. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low.
J Nephrol
. 2016 Feb; 29(1): 63–70.
14.
Sprague SM, Crawford PW, Melnick JZ, Strugnell SA, Ali S, Mangoo-Karim R, et al. Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease.
Am J Nephrol
. 2016; 44(4): 316–25.
15.
Visser M, Deeg DJ, Puts MT, Seidell JC, Lips P. Low serum concentrations of 25-hydroxyvitamin D in older persons and the risk of nursing home admission.
Am J Clin Nutr
. 2006 Sep; 84(3): 616–22.
16.
Jia X, Aucott LS, McNeill G. Nutritional status and subsequent all-cause mortality in men and women aged 75 years or over living in the community.
Br J Nutr
. 2007 Sep; 98(3): 593–9.
17.
Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population.
Arch Intern Med
. 2008 Aug; 168(15): 1629–37.
18.
Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T, et al.; Women’s Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of breast cancer.
J Natl Cancer Inst
. 2008 Nov; 100(22): 1581–91.
19.
Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA, Qi D, Patel AV, Helzlsouer KJ, et al. Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: cohort consortium vitamin D pooling project of rarer cancers.
Am J Epidemiol
. 2010 Jul; 172(1): 81–93.
20.
Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G, et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries.
Int J Cancer
. 2004 Jan; 108(1): 104–8.
21.
Sprague SM, Strugnell SA, Bishop CW. Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease.
Expert Rev Endocrinol Metab
. 2017 Sep; 12(5): 289–301.
22.
Al-Aly Z, Qazi RA, González EA, Zeringue A, Martin KJ. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD.
Am J Kidney Dis
. 2007 Jul; 50(1): 59–68.
23.
Zisman AL, Hristova M, Ho LT, Sprague SM. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.
Am J Nephrol
. 2007; 27(1): 36–43.
24.
Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, et al. Vitamin D levels and patient outcome in chronic kidney disease.
Kidney Int
. 2009 Jan; 75(1): 88–95.
25.
Mehrotra R, Kermah DA, Salusky IB, Wolf MS, Thadhani RI, Chiu YW, et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States.
Kidney Int
. 2009 Nov; 76(9): 977–83.
26.
Pilz S, Tomaschitz A, Friedl C, Amrein K, Drechsler C, Ritz E, et al. Vitamin D status and mortality in chronic kidney disease.
Nephrol Dial Transplant
. 2011 Nov; 26(11): 3603–9.
27.
de Boer IH, Katz R, Chonchol M, Ix JH, Sarnak MJ, Shlipak MG, et al. Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate.
Clin J Am Soc Nephrol
. 2011 Sep; 6(9): 2141–9.
28.
Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Jain A, Schreiber MJ Jr, et al. Low 25-hydroxyvitamin D levels and mortality in non-dialysis-dependent CKD.
Am J Kidney Dis
. 2011 Oct; 58(4): 536–43.
29.
Levin A, Tang M, Perry T, Zalunardo N, Beaulieu M, Dubland JA, et al. Randomized controlled trial for the effect of vitamin D supplementation on vascular stiffness in CKD.
Clin J Am Soc Nephrol
. 2017 Sep; 12(9): 1447–60.
30.
Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D.
J Nutr
. 2005 Feb; 135(2): 317–22.
31.
Holick MF. Vitamin D for health and in chronic kidney disease.
Semin Dial
. 2005 Jul-Aug; 18(4): 266–75.
32.
Towler DA, Demer LL. Thematic series on the pathobiology of vascular calcification: an introduction.
Circ Res
. 2011 May; 108(11): 1378–80.
33.
Deluca HF, Prahl JM, Plum LA. 1,25-Dihydroxyvitamin D is not responsible for toxicity caused by vitamin D or 25-hydroxyvitamin D.
Arch Biochem Biophys
. 2011 Jan; 505(2): 226–30.
34.
Bikle DD. Clinical counterpoint: vitamin D: new actions, new analogs, new therapeutic potential.
Endocr Rev
. 1992 Nov; 13(4): 765–84.
35.
Hughes MR, Baylink DJ, Jones PG, Haussler MR. Radioligand receptor assay for 25-hydroxyvitamin D2/D3 and 1 alpha, 25-dihydroxyvitamin D2/D3.
J Clin Invest
. 1976 Jul; 58(1): 61–70.
36.
Jones G. Pharmacokinetics of vitamin D toxicity.
Am J Clin Nutr
. 2008 Aug; 88(2): 582S–6S.
37.
Shephard RM, Deluca HF. Plasma concentrations of vitamin D3 and its metabolites in the rat as influenced by vitamin D3 or 25-hydroxyvitamin D3 intakes.
Arch Biochem Biophys
. 1980 Jun; 202(1): 43–53.
38.
Torres U, Cozzolino PA, Vervloet M, editors.
Vitamin D in chronic kidney disease
. New York (NY): Springer Berlin Heidelberg; 2016.
39.
Durup D, Jørgensen HL, Christensen J, Tjønneland A, Olsen A, Halkjær J, et al. A reverse J-shaped association between serum 25-hydroxyvitamin D and cardiovascular disease mortality: the COPD study.
J Clin Endocrinol Metab
. 2015 Jun; 100(6): 2339–46.
40.
Shardlow A, McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.
BMJ Open
. 2017 Aug; 7(8):e016528.
41.
West SL, Patel P, Jamal SA. How to predict and treat increased fracture risk in chronic kidney disease.
J Intern Med
. 2015 Jul; 278(1): 19–28.
42.
Rødbro LL, Bislev LS, Sikjær T, Rejnmark L. Bone metabolism, density, and geometry in postmenopausal women with vitamin D insufficiency: a cross-sectional comparison of the effects of elevated parathyroid levels.
Osteoporos Int
. 2018 Oct; 29(10): 2211–8.
43.
Tomiyama C, Carvalho AB, Higa A, Jorgetti V, Draibe SA, Canziani ME. Coronary calcification is associated with lower bone formation rate in CKD patients not yet in dialysis treatment.
J Bone Miner Res
. 2010 Mar; 25(3): 499–504.
44.
Dusso A, Lopez-Hilker S, Rapp N, Slatopolsky E. Extra-renal production of calcitriol in chronic renal failure.
Kidney Int
. 1988 Sep; 34(3): 368–75.
45.
Ritter CS, Haughey BH, Armbrecht HJ, Brown AJ. Distribution and regulation of the 25-hydroxyvitamin D3 1α-hydroxylase in human parathyroid glands.
J Steroid Biochem Mol Biol
. 2012 May; 130(1-2): 73–80.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.